MID ATLANTIC RETINA
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1974-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:3
Trial Phases
1 Phases
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (100.0%)A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
Not Applicable
- Conditions
- Central Retinal Vein OcclusionChoroidal NeovascularizationAge-related Macular DegenerationBranch Retinal Vein Occlusion
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Mid Atlantic Retina
- Target Recruit Count
- 30
- Registration Number
- NCT01531842
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy
Not Applicable
Completed
- Conditions
- Macular HoleRetinal Detachment
- Interventions
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Mid Atlantic Retina
- Target Recruit Count
- 21
- Registration Number
- NCT01257698
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
Omega-3-fatty Acids on Age-related Macular
Not Applicable
Completed
- Conditions
- Aged Macular Degeneration
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Mid Atlantic Retina
- Target Recruit Count
- 25
- Registration Number
- NCT01258335
- Locations
- 🇺🇸
Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments
Not Applicable
Completed
- Conditions
- Retinal DetachmentVitrectomyProliferative VitreoretinopathyDiabetic Retinopathy
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Mid Atlantic Retina
- Target Recruit Count
- 15
- Registration Number
- NCT01255293
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
News
EYP-1901 Shows Promising Results in VERONA Trial for Diabetic Macular Edema
EYP-1901, a novel treatment containing varolanib in a bio-erodible polymer, outperformed aflibercept in vision improvement and disease control for diabetic macular edema in the VERONA trial.